1.08
price down icon8.47%   -0.10
after-market 시간 외 거래: 1.06 -0.02 -1.85%
loading
전일 마감가:
$1.18
열려 있는:
$1.17
하루 거래량:
2.40M
Relative Volume:
2.41
시가총액:
$139.51M
수익:
-
순이익/손실:
$-26.91M
주가수익비율:
-4.9091
EPS:
-0.22
순현금흐름:
$-19.57M
1주 성능:
+6.93%
1개월 성능:
+35.27%
6개월 성능:
+83.14%
1년 성능:
-22.30%
1일 변동 폭
Value
$1.05
$1.20
1주일 범위
Value
$0.9702
$1.29
52주 변동 폭
Value
$0.5526
$1.66

Atossa Therapeutics Inc Stock (ATOS) Company Profile

Name
명칭
Atossa Therapeutics Inc
Name
전화
206.588.0256
Name
주소
10202 5TH AVENUE NE, SEATTLE, WA
Name
직원
13
Name
트위터
@atossainc
Name
다음 수익 날짜
2025-03-25
Name
최신 SEC 제출 서류
Name
ATOS's Discussions on Twitter

ATOS을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
ATOS
Atossa Therapeutics Inc
1.08 152.42M 0 -26.91M -19.57M -0.22
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
407.79 106.37B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
460.46 59.90B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.63 60.40B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
796.92 49.56B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
320.10 36.88B 4.56B -176.77M 225.30M -1.7177

Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2018-01-26 개시 Maxim Group Buy

Atossa Therapeutics Inc 주식(ATOS)의 최신 뉴스

pulisher
12:49 PM

Regression analysis insights on Atossa Therapeutics Inc. performancePortfolio Gains Summary & High Accuracy Trade Signal Alerts - newser.com

12:49 PM
pulisher
12:07 PM

What MACD and RSI say about Atossa Therapeutics Inc.July 2025 Institutional & High Conviction Buy Zone Picks - newser.com

12:07 PM
pulisher
Oct 12, 2025

Can Atossa Therapeutics Inc. (YAG2) stock stage a strong rebound this quarterWeekly Investment Recap & Weekly Watchlist of Top Performers - newser.com

Oct 12, 2025
pulisher
Oct 11, 2025

Can a trend reversal in Atossa Therapeutics Inc. lead to recoveryEarnings Growth Report & Stepwise Swing Trade Plans - newser.com

Oct 11, 2025
pulisher
Oct 10, 2025

Atossa Therapeutics and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Pueblo Chieftain

Oct 10, 2025
pulisher
Oct 10, 2025

Is Atossa Therapeutics Inc. stock ready for a breakoutJuly 2025 Sector Moves & Breakout Confirmation Alerts - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

How to forecast Atossa Therapeutics Inc. trends using time seriesGap Down & Weekly Market Pulse Updates - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Is Atossa Therapeutics Inc. stock entering bullish territoryMarket Growth Report & Fast Moving Stock Trade Plans - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Comparing Atossa Therapeutics Inc. in custom built stock radars2025 Earnings Surprises & Stepwise Entry and Exit Trade Signals - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Published on: 2025-10-10 02:05:17 - newser.com

Oct 10, 2025
pulisher
Oct 09, 2025

Weiss Ratings Reiterates "Sell (D-)" Rating for Atossa Genetics (NASDAQ:ATOS) - MarketBeat

Oct 09, 2025
pulisher
Oct 09, 2025

Can Atossa Therapeutics Inc. (YAG2) stock deliver double digit returnsOptions Play & Weekly Breakout Watchlists - newser.com

Oct 09, 2025
pulisher
Oct 09, 2025

Signal strength of Atossa Therapeutics Inc. stock in tech scannersTrade Entry Report & Weekly Momentum Picks - newser.com

Oct 09, 2025
pulisher
Oct 09, 2025

Can Atossa Therapeutics Inc. (YAG2) stock reach $200 price targetQuarterly Trade Report & Low Volatility Stock Recommendations - newser.com

Oct 09, 2025
pulisher
Oct 07, 2025

Atossa Therapeutics (ATOS) Announces Upcoming Virtual Meeting - GuruFocus

Oct 07, 2025
pulisher
Oct 06, 2025

Atossa streamlines breast cancer trial to focus on 2026 NDA plans - Investing.com

Oct 06, 2025
pulisher
Oct 06, 2025

Atossa Therapeutics streamlines Evangeline breast cancer clinical trial to prioritize for 2026 NDA-enabling activities - MarketScreener

Oct 06, 2025
pulisher
Oct 06, 2025

40–65-Patient EVANGELINE Redesign: Atossa Prioritizes 2026 NDA‑Enabling Activities, Reduces Study Costs - Stock Titan

Oct 06, 2025
pulisher
Oct 06, 2025

Atossa Therapeutics Inc. stock retracement – recovery analysisEarnings Growth Report & Free Fast Gain Swing Trade Alerts - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

Can Atossa Therapeutics Inc. stock hit analyst price targetsWeekly Risk Report & Consistent Income Trade Recommendations - newser.com

Oct 06, 2025
pulisher
Oct 02, 2025

Atossa Therapeutics appoints Janet Rea as SVP of R&D By Investing.com - Investing.com Nigeria

Oct 02, 2025
pulisher
Oct 01, 2025

Atossa Therapeutics appoints Janet Rea as SVP of R&D - Investing.com

Oct 01, 2025
pulisher
Oct 01, 2025

What drives Atossa Therapeutics Inc YAG2 stock priceDouble Top/Bottom Patterns & Superior Trading Ideas - earlytimes.in

Oct 01, 2025
pulisher
Oct 01, 2025

Atossa Therapeutics Names Janet R. Rea, MSPH, as Senior Vice President, R&D to Accelerate (Z)-Endoxifen Toward Key Regulatory Milestones - StreetInsider

Oct 01, 2025
pulisher
Oct 01, 2025

Veteran Drug Approval Expert Returns to Atossa Therapeutics to Advance Breakthrough Breast Cancer Treatment - Stock Titan

Oct 01, 2025
pulisher
Sep 30, 2025

Goldman Sachs Group Inc. Lowers Holdings in Atossa Genetics Inc. $ATOS - Defense World

Sep 30, 2025
pulisher
Sep 29, 2025

NioCorp and Atossa Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - The Daily Jeffersonian

Sep 29, 2025
pulisher
Sep 28, 2025

What analysts say about Atossa Therapeutics Inc stockSector-Based Investing & Build Capital Safely - earlytimes.in

Sep 28, 2025

Atossa Therapeutics Inc (ATOS) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Atossa Therapeutics Inc 주식 (ATOS) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Remmel H. Lawrence
Director
Mar 26 '25
Buy
0.70
10,000
7,000
10,257
$21.35
price down icon 5.74%
$83.80
price down icon 1.12%
$31.81
price down icon 0.13%
$102.06
price down icon 2.32%
$162.33
price down icon 1.26%
biotechnology ONC
$320.10
price down icon 4.68%
자본화:     |  볼륨(24시간):